Boan Biotech, a holding subsidiary of Luye Pharma Group, will present an abstract about the preclinical data on its CD3/CEA bispecific antibody program at the American Association for Cancer Research ...
Luye Pharma Group announced that the clinical trial application for LY01015 (Nivolumab Injection) developed by the Group's subsidiary Boan Biotech, has been accepted by the Center for Drug Evaluat...
Luye Pharma Group today announced that Shandong Boan Biotechnology Co. Ltd. (Boan Biotech) has completed the first patient dosing in the phase Ⅲ clinical trial for LY09004 in China. As a key area for...
Luye Pharma Group announced that its subsidiary, Shandong Boan Biotechnology Co. Ltd. (Boan Biotech), has received a further RMB 195 million in investments from investors including CCB International a...
Luye Pharma Group today announced that all subjects have been enrolled for the phase I clinical trial in China for LY-CovMab, an innovative antibody product developed by Shandong Boan Biotechnology Co...
Luye Pharma Group announced the conclusion of a round of strategic financing for its subsidiary, Shandong Boan Biotechnology Co., Ltd. (Boan Biotech), bringing cumulative financing to RMB 682 million....
Follow me
鲁公网安备37069102000284